Evaluation of the effect of Elaeagnus angustifolia in patients with mild to moderate Benign Prostatic Hyperplasia symptom

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150622022869N8

Enrollment

Registered

2021-11-01

Start date

2021-10-29

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia. Benign neoplasm of prostate

Interventions

Intervention 1: Intervention group: Capsules containing 600 mg of hydroalcoholic extract of Elm fruit, which is extracted at Yasouj University of Medical Sciences and entered into the capsule, is give

Eligibility

Sex/Gender

Male

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: A patient with a diagnosis of benign prostatic hyperplasia with an IPSS score below 21

Exclusion criteria

Exclusion criteria: Patients with a diagnosis of BPH with an IPSS score above 21

Design outcomes

Primary

Measure	Time frame
IPSS (International prostate symptom score)questionnaire score. Timepoint: At the beginning of the study and 30 dimensions, the IPSS (International prostate symptom score)questionnaire is filled out for patients (at the same time as the end of the capsules). Method of measurement: IPSS (International prostate symptom score).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMoslem Sedaghattalab

Yasouj University of Medical Sciences

m.sedaghattalab@yums.ac.ir+98 74 3322 0163

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026